Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 11

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 11
Chunk 11
---
 date. However, there is no guarantee that we will be able to use the ELOC to the extent necessary to finance our operations

In
our opinion, the environment for financing of small and micro-cap biotech companies remains challenging. While this may present acquisition
and/or merger opportunities with other companies with limited or no access to financing, as noted above, any attendant financings by us
are likely to be dilutive. We continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially
available to the Company. Any alternatives considered are contingent upon the agreement of counterparties and accordingly, there can be
no assurance that any alternative courses of action to finance the Company would be successful.

This
requirement for additional financing represents a material uncertainty that raises substantial doubt about our ability to continue as
a going concern. As a result, our independent registered public accounting firm included an explanatory paragraph in its report on our
financial statements as of and for the year ended December 31, 2024 with respect to this uncertainty. Should it become evident in the
future that there are no realistic financing options available to us which are actionable before our cash resources run out then we will
no longer be a going concern. In such circumstances, we would no longer be able to prepare financial statements under paragraph 25 of
IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would be stated at net realizable value and
all liabilities would be accelerated to current liabilities.

  110  

  Table of Contents  

Our
ability to continue as a going concern is dependent upon our ability to obtain additional capital and/or dispose of assets, for which
there can be no assurance we will be able to do on a timely basis, on favorable terms or at all.

For more information, see“ Item 5. Operating and Financial Review and Prospects - A. Operating Results - Critical Accounting Estimates and Judgments - Going
Concern.”

ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.